Earlier this year, the global market for anti-obesity medications (AOMs) reached $6 billion on an annualized basis. By 2030, it could grow by more than 16 times to $100 billion, according to Goldman Sachs Research.
General Catalyst CEO Hemant Taneja on mission-driven investing, health assurance, and AI’s transformation advantage
General Catalyst CEO Hemant Taneja shares his insights on the venture capital landscape, society’s digital transformation, and the firm’s mission-based approach to investing in the latest episode of Goldman Sachs Exchanges: Great Investors.
The global pharmaceutical sector has around $700 billion at its disposal to acquire other companies and invest in research and development, according to Goldman Sachs Research. That war chest will be important as patents expire for some of the industry’s blockbuster drugs.
Healthcare — one of the largest sectors of the U.S. economy — is among the many industries with significant opportunities for the use of artificial intelligence (AI) and machine learning (ML), says Salveen Richter, lead analyst for the U.S. biotechnology sector at Goldman Sachs Research.
Samarth Kulkarni, CEO, CRISPR Therapeutics, discusses the current state of biotechnology, the opportunities for CRISPR gene-editing therapies – and their implications for the larger pharmaceutical industry – as well as his experience leading a young company at the cutting edge of technology.
Ryan Watts, CEO and co-founder of Denali Therapeutics, discusses his company’s mission, the progress it has made in the battle against neurodegenerative diseases, and how his personal experience of losing his mother to Alzheimer’s has underscored the urgency to develop cutting-edge therapies in this field.
Kate Ryder, founder and CEO of Maven Clinic, discusses her experience launching a startup, her efforts to eliminate gender inequity in the healthcare system, and her perspective on the future of telemedicine.
In this episode of Exchanges at Goldman Sachs, Salveen Richter, Lead Analyst for the U.S. Biotechnology Sector in Goldman Sachs Research, explains how new innovations in gene editing are transforming the future of medicine and the greater biotech investment landscape.
Dr. Scott Gottlieb, Author of Uncontrolled Spread; Former FDA Commissioner; Board Member, Pfizer and Illumina
Dr. Scott Gottlieb, former FDA commissioner, Pfizer and Illumina board member, and author of Uncontrolled Spread, discusses the threat of the Omicron variant, lessons learned from the collective response to the pandemic, and prescriptions for how the country can better prepare for the next outbreak.
How has the healthcare sector fared during the pandemic? We spoke with Jenny Chang, a portfolio manager who covers healthcare for Goldman Sachs Asset Management’s Fundamental Equity team, on the sectors she and her team are focused on this year.
The hospitals and healthcare systems that are critical to managing our health are also a significant part of the institutional investor landscape. We sat down with Paget MacColl, co-head of the Americas Institutional Client Business within Goldman Sachs Asset Management (GSAM), to discuss the results of GSAM’s 2020 Healthcare Diagnostic, an annual survey assessing the investment approaches and practices of 42 leading healthcare systems and hospitals across the U.S. representing more than $350 billion in investments.
Salveen Richter, lead analyst for the US Biotechnology sector in Goldman Sachs Research, talks about Pfizer’s clinical-trial results for its COVID-19 vaccine and the obstacles that still lie ahead for FDA approval and widespread distribution.
Amid many concerns heading into 2020, the event that no one expected was the outbreak of COVID-19—a coronavirus that first emerged in the populous city of Wuhan, China, and which is now proving to be both more infectious and virulent than the common flu. As China attempts to restart its economy after an unprecedented lockdown, the virus continues to spread globally, and data on the sizeable economic fallout starts to trickle in, coronavirus is Top of Mind.
The hospitals and healthcare systems that are critical to managing our health are also, with more than $1 trillion in investments, a significant part of the institutional investor landscape. We sat down with Paget MacColl of Goldman Sachs Asset Management (GSAM), which recently released the results of its Healthcare Diagnostic, an annual survey assessing the investment approaches and practices of the nation’s largest nonprofit healthcare systems and hospitals. In our interview, Paget discussed the role of investments amid an increasingly challenging operating environment.
Marshall Smith, global head of healthcare investment banking at Goldman Sachs, discusses how healthcare corporations are driving growth amid macro and industry-specific uncertainty. Listen Now